0% found this document useful (0 votes)
56 views15 pages

Boala Hodgkin

This document defines Hodgkin's disease and provides details about its epidemiology, classification, clinical presentation, diagnostic process, and treatment. Specifically, it is a rare lymphoma comprising 1% of cancers. It presents with painless swollen lymph nodes and can spread to the spleen, liver, or bone marrow. Diagnosis is made through lymph node biopsy showing Reed-Sternberg cells. Treatment involves chemotherapy, radiation therapy, or a combination to cure about 80% of cases. Complications can include digestive issues, alopecia, infections, and cytopenias.

Uploaded by

Paun Florina
Copyright
© © All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as PPT, PDF, TXT or read online on Scribd
0% found this document useful (0 votes)
56 views15 pages

Boala Hodgkin

This document defines Hodgkin's disease and provides details about its epidemiology, classification, clinical presentation, diagnostic process, and treatment. Specifically, it is a rare lymphoma comprising 1% of cancers. It presents with painless swollen lymph nodes and can spread to the spleen, liver, or bone marrow. Diagnosis is made through lymph node biopsy showing Reed-Sternberg cells. Treatment involves chemotherapy, radiation therapy, or a combination to cure about 80% of cases. Complications can include digestive issues, alopecia, infections, and cytopenias.

Uploaded by

Paun Florina
Copyright
© © All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as PPT, PDF, TXT or read online on Scribd
You are on page 1/ 15

BOALA

HODGKIN
DEFINITIE

 Neoplazie a tesutului limfoid

 – 1% din totalul neoplasmelor


 - 30% din totalul limfoamelor

B. Hodgkin = LIMFOM CU CELULE B


derivate din centrul germinal
Date de epidemiologie
 Incidenta
 Boala rara – 2-3/100.000 loc. in Europa, SUA
 Repartitie bimodala a incidentei pe grupe de
varsta:

20- 29 ani > 60 ani


CD 30+
Clasificarea histopatologica REAL
 Limfom Hodgkin nodular predominant limfocitar

PROGNOSTIC
 Limfom Hodgkin clasic
 Bogat limfocitar

 Scleroza nodulara

 Celularitate mixta

 Depletie limfocitara
Tablou clinic
 Debut – adenopatii elastice, nedureroase – cel
mai frecvent laterocervicale, supraclaviculare
Tablou clinic
 Splenomegalia ~ 30% cazuri
 De obicei asociata cu adenopatii abdominale
 Hepatomegalia 5%
 Masele tumorale mari (bulky, > 10 cm) pot determina
sdr. compresive:
 mediastinale sau hilare - dispnee sau sindrom mediastinal,
compresie VCS;
 hilare hepatice – colestaza,
 abdominale – sdr subocluzive;
 retroperitoneale – anurie, IR postrenala
 Extensie directa la nivel pummonar, pericardic
(pericardita), pleural (pleurezie), costal (lize), etc
Tablou clinic
 In general, in stadiile initiale - extensie prin
contiguitate – la lanturile ggl invecinate

 Diseminarea hematogena – in general in stadii


avansate, evolutive – poate afecta MO, organe
parenchimatoase (ficat, plaman); trebuie
diferentiata de extensia prin contiguitate de la o
masa tumorala de vecinatate
Tablou clinic
 Simptome generale ~33% din cazuri la debut
 Simptome “B”: 1)↓ Greut. > 10% in ultimele 6 luni,
2) febra neexplicata, 3) transpiratii profuze nocturne
 Altele: prurit generalizat; durere ganglionara dupa
ingestia de alcool; astenie; paloare  icter

 Suceptibilitate la infectii (defect imunitate


celulara): TBC, fungi, virale (HZV), protozoare
(P. carinii)
Paraclinic
 HG: - anemie normocroma, normocitara (ACS, AHAI – std
avansate)
- leucocitoza moderata, limfopenie, eozinofilie
- trombocitoza reactiva
 Sdr. Inflamator : VSH, Fbg, PCR
 Ex MO: modif reactive; det LH – std IV
 Hiperuricemie
 LDH, F alcalina serica 
 BR, TGO, TGP
Diagnostic
 = HISTOPATOLOGIC
 Biopsie ganglionara excizionala
 Ganglioni periferici (laterocervicali > inghinali)
 Ganglioni profunzi (mediastinoscopie, laparotomie)

 Biopsie osoasa
 Biopsii dirijate imagistic din organe afectate
primar (ficat, plaman…)
Tratament
 In lipsa tratamentului – 90% mortalitate in decurs de
2-3 ani
 Terapii actuale – curabilitate 80%
 STRATEGIE TERAPEUTICA
- obiectiv: de a oferi fiecarui pacient cea mai mare
sansa de vindecare in conditiile unui risc cat mai scazut
de morbiditate cauzata de tratament
- in functie de factori prognostici legati de boala si
legati de pacient
Tratament
 RADIOTERAPIE (RxT)
 CHIMIOTERAPIE (PCT)
 Scheme de polichimioterapie – contin 4 – 7 agenti
citostatici
 Administrare periodica – cicluri de 21 – 28 zile

 Nr de cicluri – dependent de stadiul de boala, protocolul


terapeutic
 COMBINATIE RADIOTERAPIE -
CHIMIOTERAPIE
Tratament – masuri generale
 Hidratare > 3000 ml/zi + diureza coresp.
 Hipouricemiante + alcalinizarea urinii
 Antiemetice
 Profilaxia infectiilor (Biseptol, Aciclovir)
 Factori de crestere (G-CSF, Epo)
 Protectoare gastrice
 Tratamentul durerii, depresiei…
Complicatiile tratamentului
 Immediate
 Digestive – inapetenta, greata, varsaturi
 Allopecie

 Dermatologice - Pigmentari cutanate, rush

 Neurologice – parestezii, hipoestezii

 Hematologice – citopenii

 Cardiologice – IC

 Hepatocitoliza, colestaaza

 Hiperuricemie, IR

You might also like